Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

Verstovsek, Srdan ; Kantarjian, Hagop M. ; Estrov, Zeev ; Cortes, Jorge E. ; Thomas, Deborah A. ; Kadia, Tapan ; Pierce, Sherry ; Jabbour, Elias ; Borthakur, Gautham ; Rumi, Elisa ; Pungolino, Ester ; Morra, Enrica ; Caramazza, Domenica ; Cazzola, Mario ; Passamonti, Francesco

Blood, 2012-08, Vol.120 (6), p.1202-1209 [Periódico revisado por pares]

Washington, DC: Elsevier Inc

Texto completo disponível